Clinical trial
T138067 Sodium in Treating Patients With Advanced Refractory Cancer
NCT00003359 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003359 |
|---|---|
| Title | T138067 Sodium in Treating Patients With Advanced Refractory Cancer |
| Official title | Phase I Dose Escalation Study to Evaluate the Safety of T138067-Sodium in Patients With Advanced Refractory Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | batabulin sodium |
| Enrollment | 24 |
| Start date | Apr 1, 1998 |
| Primary completion | Jan 1, 2001 |
| Completion | Jan 1, 2001 |
| First posted | Jul 16, 2004 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: